$BLUE
bluebird bio, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015006510 Filed on August 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q4 2014 Q2
Revenue $4.940M $6.386M $6.335M
YoY Change -22.02% 0.81% 0.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.70M $5.300M $5.700M
YoY Change 87.72% 12.77% 72.73%
% of Gross Profit
Research & Development $44.27M $20.50M $13.93M
YoY Change 217.75% 109.18% 92.23%
% of Gross Profit
Depreciation & Amortization $1.800M $1.670M $540.0K
YoY Change 233.33% 406.06% 237.5%
% of Gross Profit
Operating Expenses $56.96M $25.80M $19.67M
YoY Change 189.61% 77.93% 171.41%
Operating Profit -$52.02M -$19.61M -$13.33M
YoY Change 290.15% 141.7% 217.93%
Interest Expense -$2.000M -$200.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $228.0K $100.0K $11.00K
YoY Change 1972.73% -102.83%
Pretax Income -$51.80M -$19.50M -$13.32M
YoY Change 288.76% 140.74% 190.7%
Income Tax $0.00 $0.00 -$11.80M
% Of Pretax Income
Net Earnings -$51.80M -$19.54M -$1.526M
YoY Change 3294.17% 141.85% -66.7%
Net Earnings / Revenue -1048.48% -306.04% -24.09%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.570M -$663.3K -$61.22K
COMMON SHARES
Basic Shares Outstanding 32.83M 28.82M 24.51M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2014 Q4 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $810.5M $473.6M $175.7M
YoY Change 361.3% 129.59% -23.21%
Cash & Equivalents $593.3M $347.8M $175.7M
Short-Term Investments $217.2M $125.7M
Other Short-Term Assets $4.900M $6.400M $7.200M
YoY Change -31.94% 12.28% 323.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $815.5M $480.0M $182.9M
YoY Change 345.95% 126.42% -20.67%
LONG-TERM ASSETS
Property, Plant & Equipment $16.80M $15.74M $12.86M
YoY Change 30.67% 44.14% 411.21%
Goodwill $13.13M $13.13M
YoY Change
Intangibles $28.22M $30.10M
YoY Change
Long-Term Investments $125.9M $18.40M
YoY Change
Other Assets $1.500M $1.215M $1.700M
YoY Change -11.76% -18.07% 13.33%
Total Long-Term Assets $183.7M $76.75M $57.75M
YoY Change 218.08% 518.8% 1337.36%
TOTAL ASSETS
Total Short-Term Assets $815.5M $480.0M $182.9M
Total Long-Term Assets $183.7M $76.75M $57.75M
Total Assets $999.2M $556.7M $240.6M
YoY Change 315.26% 148.11% 2.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.300M $2.954M $2.586M
YoY Change -11.06% -32.23% 60.72%
Accrued Expenses $15.30M $12.70M $11.70M
YoY Change 30.77% 159.18% 244.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.00M $42.98M $39.55M
YoY Change -29.2% 23.24% 30.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $51.80M $294.0K $352.0K
YoY Change 14615.91% 41.35% -99.18%
Total Long-Term Liabilities $51.80M $294.0K $352.0K
YoY Change 14615.91% 41.35% -99.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.00M $42.98M $39.55M
Total Long-Term Liabilities $51.80M $294.0K $352.0K
Total Liabilities $80.20M $65.48M $74.87M
YoY Change 7.12% -9.96% 2.17%
SHAREHOLDERS EQUITY
Retained Earnings -$147.4M -$110.8M
YoY Change 49.36% 31.17%
Common Stock $323.0K $251.0K
YoY Change 35.15% 6.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $919.0M $491.3M $165.8M
YoY Change
Total Liabilities & Shareholders Equity $999.2M $556.7M $240.6M
YoY Change 315.26% 148.11% 2.59%

Cashflow Statement

Concept 2015 Q2 2014 Q4 2014 Q2
OPERATING ACTIVITIES
Net Income -$51.80M -$19.54M -$1.526M
YoY Change 3294.17% 141.85% -66.7%
Depreciation, Depletion And Amortization $1.800M $1.670M $540.0K
YoY Change 233.33% 406.06% 237.5%
Cash From Operating Activities -$12.12M -$15.66M -$11.33M
YoY Change 6.97% 186.81% 37.33%
INVESTING ACTIVITIES
Capital Expenditures -$1.410M -$2.410M -$2.010M
YoY Change -29.85% -54.44% 336.96%
Acquisitions
YoY Change
Other Investing Activities -$6.580M $30.00M -$4.670M
YoY Change 40.9% 273.6%
Cash From Investing Activities -$7.990M $27.60M -$6.690M
YoY Change 19.43% -621.74% 291.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 480.2M 246.3M 1.230M
YoY Change 38943.9% 106991.3% -98.85%
NET CHANGE
Cash From Operating Activities -12.12M -15.66M -11.33M
Cash From Investing Activities -7.990M 27.60M -6.690M
Cash From Financing Activities 480.2M 246.3M 1.230M
Net Change In Cash 460.1M 258.3M -16.79M
YoY Change -2840.5% -2554.85% -117.31%
FREE CASH FLOW
Cash From Operating Activities -$12.12M -$15.66M -$11.33M
Capital Expenditures -$1.410M -$2.410M -$2.010M
Free Cash Flow -$10.71M -$13.25M -$9.320M
YoY Change 14.91% 7694.12% 19.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2014Q4 us-gaap Liabilities
Liabilities
65482000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-71000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5302000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
323000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
491257000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
294000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
556739000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
85000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
367000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-51795000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1526000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
638389000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147384000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32340000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32340000
CY2015Q2 us-gaap Revenues
Revenues
4940000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76582000
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11797000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11797000
us-gaap Net Income Loss
NetIncomeLoss
-76582000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
6250000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
228000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51795000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13323000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76949000
us-gaap Net Income Loss
NetIncomeLoss
-12135000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5738000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10724000
us-gaap Costs And Expenses
CostsAndExpenses
88233000
us-gaap Costs And Expenses
CostsAndExpenses
36671000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-52023000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13334000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51725000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16050000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24001000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6321000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1913000
CY2014Q2 us-gaap Revenues
Revenues
6335000
us-gaap Contracts Revenue
ContractsRevenue
11284000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
170000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
us-gaap Contracts Revenue
ContractsRevenue
12500000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13931000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2188000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23932000
CY2015Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1973000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44266000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
18000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24474000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32955000
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
343199000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
144229000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
492003000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
6796000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
181300000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
134400000
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
56963000
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
19669000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
70000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1526000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76564000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12135000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
blue Noncash Benefit On Release Of Income Tax Valuation Allowance
NoncashBenefitOnReleaseOfIncomeTaxValuationAllowance
11797000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3509000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1017000
us-gaap Share Based Compensation
ShareBasedCompensation
21482000
us-gaap Share Based Compensation
ShareBasedCompensation
4843000
us-gaap Other Noncash Expense
OtherNoncashExpense
269000
us-gaap Other Noncash Expense
OtherNoncashExpense
168000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1059000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-854000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-418000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2702000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1098000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7674000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
13716000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12670000
blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-480000
blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
1490000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36277000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-23258000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-359000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2568000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4534000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4673000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
261440000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
62680000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-200969000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9207000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
477179000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5521000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1896000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1896000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30569000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175710000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
43759000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
12768000
blue Noncash Or Part Noncash Acquisition Noncash Financial Equity Issued
NoncashOrPartNoncashAcquisitionNoncashFinancialEquityIssued
19348000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
524000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
344000
blue Offering Costs In Connection With Equity Financing Included In Accounts Payable And Accrued Expenses
OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayableAndAccruedExpenses
115000
blue Offering Costs In Connection With Equity Financing Included In Accounts Payable And Accrued Expenses
OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayableAndAccruedExpenses
45000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
181000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
75000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
37000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
90000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
144158000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company was formed to develop, manufacture and market therapies to safely and effectively deliver genes useful in the treatment of severe genetic and rare diseases and in the field of T cell-based immunotherapy. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, the Company sold 2,941,176 shares of common stock through an underwritten public offering at a price of $170.00 per share. The aggregate net proceeds received by the Company from the offering were $477.2 million, net of underwriting discounts and commissions and estimated offering expenses payable by the Company of approximately $22.8 million.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
77000
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2941176
CY2015Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
477200000
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
170.00
CY2015Q2 us-gaap Investment Banking Advisory Brokerage And Underwriting Fees And Commissions
InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
22800000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
343146000
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
936445000
CY2015Q2 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
7984000
CY2015Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2014Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2015Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3394000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3937000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4943000
CY2015Q2 blue Accrued Goods And Services
AccruedGoodsAndServices
10303000
CY2014Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
7358000
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1090000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
428000
CY2015Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
885000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
914000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
475000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
415000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
531000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
1300000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
900000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2351000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21482000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4843000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3652000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
915000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
671000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
43000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3853000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1325000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3776000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
106.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
44.68
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.15
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.89
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
35.61
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5300000
CY2015Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
blue Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
blue Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4331000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4571000

Files In Submission

Name View Source Status
0001564590-15-006510-index-headers.html Edgar Link pending
0001564590-15-006510-index.html Edgar Link pending
0001564590-15-006510.txt Edgar Link pending
0001564590-15-006510-xbrl.zip Edgar Link pending
blue-10q_20150630.htm Edgar Link pending
blue-20150630.xml Edgar Link completed
blue-20150630.xsd Edgar Link pending
blue-20150630_cal.xml Edgar Link unprocessable
blue-20150630_def.xml Edgar Link unprocessable
blue-20150630_lab.xml Edgar Link unprocessable
blue-20150630_pre.xml Edgar Link unprocessable
blue-ex1014_526.htm Edgar Link pending
blue-ex1021_245.htm Edgar Link pending
blue-ex1029_176.htm Edgar Link pending
blue-ex311_7.htm Edgar Link pending
blue-ex312_9.htm Edgar Link pending
blue-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20150806212603816844.jpg Edgar Link pending
g20150806212606644844.jpg Edgar Link pending
g20150806212607378845.jpg Edgar Link pending
g20150806212608191846.jpg Edgar Link pending
g20150806212608394847.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending